Biogen estimates raised by Merrill Lynch

Biogen Idec Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating following second-quarter earnings but raised the 2005 EPS estimate to $1.67 per share from $1.39 due to reduced spending, higher interest and fewer shares. Biogen shares Wednesday gained $0.66, or 1.70%, to close at $39.48 on volume of 8,828,251 shares versus the three-month running average of 4,476,920 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.